BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/01/2026 07:38 PDT] BLRX Expected to Trade Up After Bullish Patterns Develop
• [05/28/2026 14:17 PDT] BioLineRx Ltd. (NASDAQ:BLRX), Up By 100% ($3.1) From $3.1 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/28/2026 12:42 PDT] BioLineRx Ltd. (NASDAQ:BLRX), Up By 100% ($2.86) From $2.86 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/22/2026 07:15 PDT] BLRX Expected to Trade Up After Bullish Patterns Develop
• [05/19/2026 10:29 PDT] BioLineRx Ltd. (NASDAQ:BLRX), Down By 100% ($3.11) From $3.11 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/13/2026 07:21 PDT] BLRX Expected to Trade Down After Bearish Patterns Develop
• [05/08/2026 07:10 PDT] BLRX Expected to Trade Up After Bullish Patterns Develop
• [04/30/2026 07:17 PDT] BLRX Expected to Trade Up After Bullish Patterns Develop
• [04/29/2026 12:42 PDT] BioLineRx Ltd. (NASDAQ:BLRX), Up By 100% ($2.39) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, March 24th 2026 at a Price of $2.39.
• [04/29/2026 11:07 PDT] BioLineRx Ltd. (NASDAQ:BLRX), Up By 100% ($2.36) After BUYINS.NET SqueezeTrigger Report Released on Monday, April 27th 2026 at a Price of $2.36.
• [04/28/2026 14:17 PDT] BioLineRx Ltd. (NASDAQ:BLRX), Up By 100% ($2.35) After BUYINS.NET SqueezeTrigger Report Released on Thursday, April 23rd 2026 at a Price of $2.35.
• [04/27/2026 11:07 PDT] BLRX SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [04/23/2026 08:54 PDT] BLRX SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [04/22/2026 04:00 PDT] BLRX Expected to Trade Down After Bearish Patterns Develop
• [04/09/2026 07:00 PDT] BLRX Expected to Trade Down After Bearish Patterns Develop